Magda Kosmopoulou
University of Bristol(GB)
Publications by Year
Research Areas
Carbohydrate Chemistry and Synthesis, Biochemical and Molecular Research, Glycogen Storage Diseases and Myoclonus, Microtubule and mitosis dynamics, Antibiotic Resistance in Bacteria
Most-Cited Works
- → Cross-class metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes(2016)142 cited
- → Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase(2015)111 cited
- → Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design(2010)97 cited
- → Kinetic and crystallographic studies on 2‐(β‐D‐glucopyranosyl)‐5‐methyl‐1, 3, 4‐oxadiazole, ‐benzothiazole, and ‐benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site(2005)86 cited
- → Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate(2010)81 cited
- → Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells(2013)77 cited
- → Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes(2005)71 cited
- → Binding of N‐acetyl‐N ′‐β‐d‐glucopyranosyl urea and N‐benzoyl‐N ′‐β‐d‐glucopyranosyl urea to glycogen phosphorylase b(2002)70 cited
- → Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia(2012)69 cited
- → High‐resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure‐based design of ribonucleolytic inhibitors(2003)55 cited